Search Orphan Drug Designations and Approvals
-
| Generic Name: | an ADC drug against CLDN18.2, containing a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody and linker-payload MC-VC-PAB-MMAE |
|---|---|
| Date Designated: | 11/30/2021 |
| Orphan Designation: | Treatment of Cholangiocarcinoma (intrahepatic bile duct cancer) |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
LaNova Medicines Limited 999 Cailun Road, Building 1, Floor 5 Shanghai 201203 China The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







